GRAND RAPIDS, Mich. — Padded mats are being utilized in classrooms across West Michigan as part of a cutting-edge approach to crisis de-escalation. Lauren Raap, an emotional impairment teacher at ...

or on the link below. Immune checkpoint blockers (ICBs) have revolutionized the treatment of non–small cell lung cancer (NSCLC). Currently, one-dose-fits-all maximalist regimens have been considered ...

As a senior instructor for the National De-escalation Training Center, I train law enforcement officers how to de-escalate situations that have the potential to turn violent. A couple of weeks ago I ...

The excellent cure rates documented in clinical trials today constitute a very high bar for attempts to de-escalate therapy for early-stage breast cancer (EBC). Moreover, any therapy de-escalation ...

NORTH TEXAS – When it comes to keeping communities safe, police officers want to be prepared. That's why the White Settlement Police Department has introduced virtual reality headsets to immerse ...

Many people, within the course of their employment, encounter individuals who potentially pose a threat to themselves or others. This dilemma is faced by security professionals, healthcare ...

Seminoma, the commonest type of testicular cancer, has a great treatment success rate, with 3-year progression-free survival (PFS) rates of at least 90%. However, the treatment regimen is intense, ...

PROVIDENCE – When David E. Lambert began his law enforcement career more than three decades ago, there was little talk of mental illness or the impact of post-traumatic stress disorder. The powerful ...

In a Friday evening lecture, President of Heartland Alliance Evelyn Diaz and Prof. Jens Ludwig, public policy, University of Chicago, argued that insights from behavioral science could be critical for ...

Every law enforcement officer in South Carolina receives training from the South Carolina Criminal Justice Academy, and this ...

Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study Immune checkpoint blockers ...